Literature DB >> 6354236

Prevention of post-herpetic neuralgia by amantadine hydrochloride (Symmetrel).

A W Galbraith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354236

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


× No keyword cloud information.
  9 in total

1.  Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature.

Authors:  K E Schmader; S Studenski
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

2.  Postherpetic neuralgia.

Authors:  P N Robinson; N Fletcher
Journal:  J R Coll Gen Pract       Date:  1986-01

Review 3.  Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials.

Authors:  T Lancaster; C Silagy; S Gray
Journal:  Br J Gen Pract       Date:  1995-01       Impact factor: 5.386

Review 4.  Pharmacologic management of herpes zoster and postherpetic neuralgia.

Authors:  F S Mamdani
Journal:  Can Fam Physician       Date:  1994-02       Impact factor: 3.275

Review 5.  Post herpetic neuralgia: a review.

Authors:  M J Griffin; F A Chambers; R MacSullivan
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 2.089

6.  Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis.

Authors:  Junhyeok Kim; Min Kyoung Kim; Geun Joo Choi; Hwa Yong Shin; Beom Gyu Kim; Hyun Kang
Journal:  Korean J Pain       Date:  2021-10-01

7.  Effectiveness of amantadine in reducing relapses in multiple sclerosis.

Authors:  G S Plaut
Journal:  J R Soc Med       Date:  1987-02       Impact factor: 18.000

Review 8.  Zoster vaccine live for the prevention of shingles in the elderly patient.

Authors:  Jamie Zussman; Lorraine Young
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

9.  Chapter 12. Antiviral Agents.

Authors:  James L Kelley
Journal:  Annu Rep Med Chem       Date:  2008-04-10       Impact factor: 1.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.